TORONTO--(Marketwire - January 13, 2010) -
The Ontario Institute for Cancer Research (OICR)
announced today the appointments of Franklin D. Stonebanks as Vice
President, Commercialization and Chief Commercial Officer, and Nicole
Onetto, M.D. as Deputy Director.
"Since its inception a few years ago, the Ontario Institute for Cancer
Research has developed an impressive portfolio of early stage research
programs. The appointment of commercial and medical talent with deep
industry experience will help us accelerate our efforts to prevent, detect
and treat cancer," said Dr. Tom Hudson, President and Scientific Director
of the Ontario Institute for Cancer Research.
Mr. Stonebanks will lead the Institute's commercialization program
including identifying and developing opportunities to collaborate with
private equity and corporate strategic investors in oncology; spearhead the
intellectual property program to maximize OICR's extensive intellectual
property pipeline, and identify and accelerate transformative early stage
research and development projects using novel business models.
"Frank's broad and deep commercial expertise will be a major asset as OICR
seeks to forge new partnerships with corporations as well as private
capital investors," noted Dr. Hudson.
Most recently, Mr. Stonebanks was the Founder and Managing Partner of
Blackcomb Advisors LLC, a global advisory firm in the life sciences and
healthcare IT sectors. Previously, he was President and CEO of Cynvec, an
oncology-focused biotechnology firm. Prior to Cynvec, he was a Senior
Advisor to IBM, and led their healthcare and life science M&A efforts and
co-managed their venture fund. Prior to IBM he was Vice-President and
General Manager at Johnson & Johnson's venture unit, where he was also
Co-Founder of Johnson & Johnson Internal Ventures and Co-Founder and CEO of
the Macroflux Corporation, a Johnson & Johnson spin-off. Mr. Stonebanks was
also the Founder and Executive Director of the Oncology Biologics Business
Unit at Centocor.
Mr. Stonebanks holds a Bachelor of Arts degree from the University of
Victoria, a Pharmaceutical Marketing Diploma from the Amos Tuck School of
Business Administration, Dartmouth College and a Master of Business
Administration in Pharmaceutical Marketing from St. Joseph's University.
Dr. Onetto will work with OICR's scientific leaders to determine the
Institute's strategic direction and set priorities for the research
program. Dr. Onetto will also provide oversight of the Institute's support
"With an extensive background in oncology drug development and the
pharmaceutical industry, Nicole will be key in leading OICR's translational
research programs and supporting commercialization initiatives," said Dr.
Most recently, Dr. Onetto was the Senior Vice President and Chief Medical
Officer of ZymoGenetics, Inc. Previously she was the Executive Vice
President and Chief Medical Officer of OSI Pharmaceuticals Inc. She has
held several senior positions in international pharmaceutical firms and has
been responsible for the coordination of clinical trials worldwide that
developed many new cancer therapies.
Dr. Onetto led the clinical development of Tarceva® (erlotinib) for
non-small cell lung cancer and pancreatic cancer in collaboration with
National Cancer Institute of Canada. She also was the international project
leader for Taxol® (paclitaxel). She holds a Doctorate in Medicine from the
Université de Paris as well as a Master of Science in Pharmacology from the
Université de Montréal and is qualified in paediatrics and hemato-oncology.
OICR is a new, innovative cancer research institute dedicated to research
in prevention, early detection, diagnosis and treatment of cancer. The
Institute is a not-for-profit corporation funded by the Government of
Ontario through the Ministry of Research and Innovation. For more
information, visit www.oicr.on.ca.